Belgium Bioinformatics Market Report 2022 to 2030

Belgium Bioinformatics Market Analysis

$ 3999

The Belgium Bioinformatics market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be the strong presence of pharmaceutical and biotech firms as well as government funding for R&D. The market is segmented by technology and by application. Some of the major players include BioLizard (BEL), BISC Global (BEL), InSilico Genomics, Agilent Technologies, and IBM Life Sciences.

ID: IN10BEHS001 CATEGORY: Healthcare Services GEOGRAPHY: Belgium AUTHOR: Neha Davda

Buy Now

Belgium Bioinformatics Market Executive Summary

The Belgium Bioinformatics market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. In 2019, the healthcare expenditure in Belgium as a percentage of GDP was 10.66% or $4,960.39 per capita. It spent higher than the current EU average of 9.9 %. Public spending made up 77% of total health spending, which is significantly less than the average for the EU at 80%.

The field of bioinformatics combines the study of biology with information technology. Bioinformatics uses a variety of approaches, including data production, data warehousing, data mining, data management, and more. In order to provide statistical methods and data processing algorithms for applications like next-generation sequencing, modeling of genomic and proteomic structure, and three-dimensional drug discovery, bioinformatics software and tools are employed as integrated solutions. Europe has the second-largest market share in the world's bioinformatics market.

Market Dynamics

Market Growth Drivers

The Belgium bioinformatics market is expected to be driven by factors such as the strong presence of pharmaceutical and biotech firms as well as government funding for R&D. Furthermore, the nation's central location in Europe may make it a desirable destination for foreign businesses looking for expansion to increase their bioinformatics skills.

Market Restraints

The limited availability of skilled personnel along with relatively high labor costs in Belgium compared to other countries in Europe makes the bioinformatics market less attractive for companies to set up operations there.

Competitive Landscape

Key Players

BioLizard (BEL)
BISC Global (BEL)
InSilico Genomics
Agilent Technologies
IBM Life Sciences

Notable Recent Deals

February 2022: BISC Global entered into a partnership with CropSeq Bioinformatics. With this partnership, customers in the plant breeding research and industry have access to the full range of cutting-edge AgriGenomics services, including pipeline development, software engineering, cloud solutions, and many more. This combination of skills ensures that solutions are tailored to each individual customer's needs and project, delivering the outcomes in the most time- and money-efficient manner.

January 2022: BioLizard announced its strategic partnership with flanders.bio, the main life sciences cluster organization. A strong presence within the flanders.bio network will enable BioLizard to collaborate even more closely with a broad spectrum of life science stakeholders, from start-ups to major multinational organizations, both in and outside of Belgium. Through this agreement, BioLizard will further solidify its position as the industry leader in complex bioinformatics, artificial intelligence (AI), data science, and data management solutions.

Healthcare Policies and Regulatory Landscape

The healthcare system in Belgium is divided into three distinct regions: Flanders, Wallonia, and Brussels, and is primarily supported by taxes and social security contributions. The healthcare system is generally characterized by a high level of accessibility and a strong emphasis on preventive treatment, while each region has its own unique healthcare policies and regulations.

The Federal Public Service of Public Health, which is in charge of establishing national health policies and regulations and supervising their implementation by the regional governments, is responsible for monitoring the administration of the healthcare system in Belgium. The National Institute for Health and Disability Insurance (RIZIV/INAMI), which is in charge of evaluating novel therapies and technologies as well as reimbursing medical expenses, is also in charge of overseeing the system.

Reimbursement Scenario

The National Institute for Health and Disability Insurance (RIZIV/INAMI) is in charge of most aspects of healthcare service reimbursement in Belgium. Belgium's reimbursement regulations aim to ensure that patients have access to the required care and treatments while simultaneously limiting costs and fostering efficiency.

RIZIV/INAMI determines the reimbursement rates for healthcare services and treatments that are covered by the national health insurance program and maintains a list of reimbursable medications, which includes drugs that are covered by the program. These rates are determined by a number of variables, such as the price of the service or treatment, the anticipated therapeutic result, and the accessibility of alternative therapies.

In addition to public health insurance, some Belgians have private health insurance plans. These policies may offer lower cost-sharing for specific treatments as well as coverage for procedures and services that are not covered by the national health insurance program.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Belgium Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.